Research programme: antibacterial therapeutics - Eisai/Kyorin
Latest Information Update: 11 Sep 2014
At a glance
- Originator Eisai Co Ltd
- Developer Kyorin Pharmaceutical
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Bacterial infections
Most Recent Events
- 10 Sep 2014 Early research in Bacterial infections in Japan (unspecified route)